Health Canada Approves New Indication for ERLEADA®* (apalutamide) for the Treatment of Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | Markets Insider

In the Phase 3 TITAN study, ERLEADA®, in combination with androgen deprivation therapy, achieved statistical significance in dual primary endpoint…

Read the full article here

Related Articles